Natera CEO Sold Company Stock in September
CEO Steven Leonard Chapman sold 1,698 shares of Natera stock for a total value of $545,000.
Updated on Sept. 18, 2026 in Public Companies
Live Poll
Do you trust routine insider stock sales as a neutral indicator of a company's health?
On September 1, 2026, Natera CEO Steven Leonard Chapman sold 1,698 shares of the company's common stock. The transaction was executed at a weighted average price of $320.99 per share.
Why it matters
The stock sale was carried out under a Rule 10b5-1 trading plan, a mechanism that allows company insiders to sell shares according to a pre-arranged schedule to avoid concerns regarding non-public information.
Natera currently maintains a market capitalization of $52.1 billion with $2.7 billion in trailing twelve-month revenue against $192.3 million in net losses. Following the sale, Chapman retains a 0.06% equity stake in the firm.
The players
Steven Leonard Chapman
He serves as the Chief Executive Officer of Natera.
Natera
The company is a major player in the field of genetic testing and diagnostics.
The details
The transaction was facilitated by a trading plan originally adopted by Chapman in December 2023, which was subsequently amended in March 2026. This type of plan is designed to provide a structured framework for insiders to divest holdings while maintaining compliance with securities regulations.
Timeline
The Rule 10b5-1 trading plan was adopted in December 2023.
The trading plan was amended in March 2026.
The stock sale occurred on September 1, 2026.
Market Landscape
Corporate executive stock divestments occur within the strict oversight of the Securities and Exchange Commission Rule 10b5-1. This regulatory structure helps stabilize market expectations by decoupling insider sales from reactive, short-term fluctuations.
For the average retail shareholder, this sale represents a routine divestment executed under pre-established rules rather than a change in business outlook. No immediate changes to retail pricing or subscription services for Natera tests were announced as a result of the sale.
The takeaway
The executive's sale is aligned with a pre-set trading schedule, which is a common practice among senior leadership to ensure transparency. Investors should monitor future company disclosures to observe any shifts in long-term corporate strategy or valuation targets.
Further reading
For more information on the current market performance of the company, see our Public Companies coverage.
Live Poll
Do you trust routine insider stock sales as a neutral indicator of a company's health?
